AstraZeneca Expands AI Partnership with Immunai Through 2027

AstraZeneca has expanded its partnership with New York-based AI biotech company Immunai through 2027, according to Calcalist. Under the expanded agreement, Immunai is eligible to receive up to $37.5 million in 2026 and 2027 as the drugmaker continues integrating its platform into oncology drug development programs.

Technology Platform and Applications

Imunai’s AMICA-OS platform analyzes clinical immunology data at the single-cell level. AstraZeneca said it will use the system for biomarker discovery, patient stratification, dose optimization, and mechanism-of-action analysis across its oncology programs. The companies expanded the collaboration into inflammatory bowel disease research in 2025, broadening the platform’s application beyond cancer-focused work.

Partnership Evolution

The current agreement builds on a 2024 partnership to use Immunai’s platform in oncology clinical programs. The companies’ collaboration traces back to 2022, when an initial phase focused on improving oncology trials included an $18 million investment by AstraZeneca. As of September 2024, Immunai had raised approximately $270 million in total funding. The company reported that 85 of its 170 employees hold PhD or MD degrees, and stated it has secured more than 30 partnerships with Fortune 100 drug companies and leading academic institutions.